06.15.15
EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, has expanded its Provantage Biodevelopment Services to include a Clone Generation Service.
The new service includes expression of recombinant proteins such as hormones, growth factors and mono- and bi-specific monoclonal antibodies. Customers can choose from DG44 and CHO-S cell lines, both of which are widely used for high-yield production of biologics. Every clone generation is fully documented to ensure traceability from the source and demonstrate that the cell is clonal, making the cells usable for clinical production, IND submission.
"Development of a high-quality, high-expressing cell line is a critical, early step in the production of a biologic drug," said Udit Batra, president and chief executive officer of EMD Millipore. "The cell line not only defines the product, but also drives much of the yield and titer during bioproduction. Our Provantage team and services optimize clone generation as well as the entire clinical scale process, setting the stage for manufacturing success."
The new service includes expression of recombinant proteins such as hormones, growth factors and mono- and bi-specific monoclonal antibodies. Customers can choose from DG44 and CHO-S cell lines, both of which are widely used for high-yield production of biologics. Every clone generation is fully documented to ensure traceability from the source and demonstrate that the cell is clonal, making the cells usable for clinical production, IND submission.
"Development of a high-quality, high-expressing cell line is a critical, early step in the production of a biologic drug," said Udit Batra, president and chief executive officer of EMD Millipore. "The cell line not only defines the product, but also drives much of the yield and titer during bioproduction. Our Provantage team and services optimize clone generation as well as the entire clinical scale process, setting the stage for manufacturing success."